{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T18:39:53Z","timestamp":1793817593519,"version":"4.6.1"},"reference-count":37,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pathogenic gain-of-function variants in the genes encoding phosphoinositide 3-kinase \u03b4 (PI3K\u03b4) lead to accumulation of transitional B cells and senescent T cells, lymphadenopathy, and immune deficiency (activated PI3K\u03b4 syndrome [APDS]). Knowing the genetic etiology of APDS afforded us the opportunity to explore PI3K\u03b4 inhibition as a precision-medicine therapy. Here, we report in vitro and in vivo effects of inhibiting PI3K\u03b4 in APDS. Treatment with leniolisib (CDZ173), a selective PI3K\u03b4 inhibitor, caused dose-dependent suppression of PI3K\u03b4 pathway hyperactivation (measured as phosphorylation of AKT\/S6) in cell lines ectopically expressing APDS-causative p110\u03b4 variants and in T-cell blasts derived from patients. A clinical trial with 6 APDS patients was conducted as a 12-week, open-label, multisite, within-subject, dose-escalation study of oral leniolisib to assess safety, pharmacokinetics, and effects on lymphoproliferation and immune dysregulation. Oral leniolisib led to a dose-dependent reduction in PI3K\/AKT pathway activity assessed ex vivo and improved immune dysregulation. We observed normalization of circulating transitional and naive B cells, reduction in PD-1+CD4+ and senescent CD57+CD4\u2212 T cells, and decreases in elevated serum immunoglobulin M and inflammatory markers including interferon \u03b3, tumor necrosis factor, CXCL13, and CXCL10 with leniolisib therapy. After 12 weeks of treatment, all patients showed amelioration of lymphoproliferation with lymph node sizes and spleen volumes reduced by 39% (mean; range, 26%-57%) and 40% (mean; range, 13%-65%), respectively. Thus, leniolisib was well tolerated and improved laboratory and clinical parameters in APDS, supporting the specific inhibition of PI3K\u03b4 as a promising new targeted therapy in APDS and other diseases characterized by overactivation of the PI3K\u03b4 pathway. This trial was registered at www.clinicaltrials.gov as #NCT02435173.<\/jats:p>","DOI":"10.1182\/blood-2017-08-801191","type":"journal-article","created":{"date-parts":[[2017,10,2]],"date-time":"2017-10-02T20:40:22Z","timestamp":1506976822000},"page":"2307-2316","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":287,"title":["Effective \u201cactivated PI3K\u03b4 syndrome\u201d\u2013targeted therapy with the PI3K\u03b4 inhibitor leniolisib"],"prefix":"10.1182","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7881-6902","authenticated-orcid":false,"given":"V. Koneti","family":"Rao","sequence":"first","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Webster","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virgil A. S. H.","family":"Dalm","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and"},{"name":"Department of Immunology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7730-2304","authenticated-orcid":false,"given":"Anna","family":"\u0160ediv\u00e1","sequence":"additional","affiliation":[{"name":"Department of Immunology, Motol University Hospital, Prague, Czech Republic;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. Martin","family":"van Hagen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and"},{"name":"Department of Immunology, Erasmus MC, Rotterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3207-5464","authenticated-orcid":false,"given":"Steven","family":"Holland","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio D.","family":"Rosenzweig","sequence":"additional","affiliation":[{"name":"NIH Clinical Center, Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas D.","family":"Christ","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7780-9316","authenticated-orcid":false,"given":"Birgitte","family":"Sloth","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maciej","family":"Cabanski","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aniket D.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"},{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Cambridge, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"de Buck","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Doucet","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4976-0898","authenticated-orcid":false,"given":"Danilo","family":"Guerini","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kalis","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilona","family":"Pylvaenaeinen","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Soldermann","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuj","family":"Kashyap","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gulbu","family":"Uzel","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1584-468X","authenticated-orcid":false,"given":"Michael J.","family":"Lenardo","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhavalkumar D.","family":"Patel","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-0820","authenticated-orcid":false,"given":"Carrie L.","family":"Lucas","sequence":"additional","affiliation":[{"name":"National Institute of Allergy and Infectious Diseases, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9014-4360","authenticated-orcid":false,"given":"Christoph","family":"Burkhart","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, Novartis Pharma AG, Basel, Switzerland; and"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"6160","key":"2020071612082903500_B1","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1126\/science.1243292","article-title":"Phosphoinositide 3-kinase \u03b4 gene mutation predisposes to respiratory infection and airway damage","volume":"342","author":"Angulo","year":"2013","journal-title":"Science"},{"issue":"3","key":"2020071612082903500_B2","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/s10875-014-0012-9","article-title":"Mutations in PIK3CD can cause hyper IgM syndrome (HIGM) associated with increased cancer susceptibility","volume":"34","author":"Crank","year":"2014","journal-title":"J Clin Immunol"},{"issue":"1","key":"2020071612082903500_B3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/ni.2771","article-title":"Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110\u03b4 result in T cell senescence and human immunodeficiency","volume":"15","author":"Lucas","year":"2014","journal-title":"Nat Immunol"},{"issue":"6","key":"2020071612082903500_B4","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1016\/j.jaci.2016.03.055","article-title":"Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase \u03b4 syndrome-like immunodeficiency","volume":"138","author":"Tsujita","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2020071612082903500_B5","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1172\/JCI75746","article-title":"A human immunodeficiency caused by mutations in the PIK3R1 gene","volume":"124","author":"Deau","year":"2014","journal-title":"J Clin Invest"},{"issue":"1","key":"2020071612082903500_B6","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jaci.2016.03.022","article-title":"Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase \u03b4 syndrome 2: a cohort study","volume":"138","author":"Elkaim","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"13","key":"2020071612082903500_B7","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1084\/jem.20141759","article-title":"Heterozygous splice mutation in PIK3R1 causes human immunodeficiency with lymphoproliferation due to dominant activation of PI3K","volume":"211","author":"Lucas","year":"2014","journal-title":"J Exp Med"},{"key":"2020071612082903500_B8","doi-asserted-by":"crossref","DOI":"10.1111\/pai.12585","article-title":"Activated PI3K\u03b4 syndrome type 2: two patients, a novel mutation, and review of the literature","volume-title":"Pediatr Allergy Immunol","author":"Olbrich","year":"2016"},{"issue":"9","key":"2020071612082903500_B9","doi-asserted-by":"crossref","first-page":"4330","DOI":"10.1073\/pnas.94.9.4330","article-title":"P110delta, a novel phosphoinositide 3-kinase in leukocytes","volume":"94","author":"Vanhaesebroeck","year":"1997","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6165","key":"2020071612082903500_B10","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/332644a0","article-title":"Type I phosphatidylinositol kinase makes a novel inositol phospholipid, phosphatidylinositol-3-phosphate","volume":"332","author":"Whitman","year":"1988","journal-title":"Nature"},{"issue":"8","key":"2020071612082903500_B11","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1073\/pnas.1617244114","article-title":"Conformational disruption of PI3K\u03b4 regulation by immunodeficiency mutations in PIK3CD and PIK3R1","volume":"114","author":"Dornan","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"issue":"11","key":"2020071612082903500_B12","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri.2016.93","article-title":"PI3K\u03b4 and primary immunodeficiencies","volume":"16","author":"Lucas","year":"2016","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"2020071612082903500_B13","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.jaci.2016.08.028","article-title":"Abnormal B-cell maturation in the bone marrow of patients with germline mutations in PIK3CD","volume":"139","author":"Dulau Florea","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2020071612082903500_B14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.clim.2017.05.020","article-title":"A novel germline gain-of-function variant in PIK3CD","volume":"181","author":"Rae","year":"2017","journal-title":"Clin Immunol"},{"key":"2020071612082903500_B15","author":"Takashima"},{"key":"2020071612082903500_B16","article-title":"Novel PIK3CD mutations affecting N-terminal residues of p1100\u03b4 cause activated PI3K\u03b4 syndrome (APDS) in humans","author":"Takeda","journal-title":"J Allergy Clin Immunol"},{"key":"2020071612082903500_B17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clim.2017.01.004","article-title":"Genetic defects in PI3K\u03b4 affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections","volume":"176","author":"Wentink","year":"2017","journal-title":"Clin Immunol"},{"issue":"2","key":"2020071612082903500_B18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2016.06.021","article-title":"Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: a large patient cohort study","volume":"139","author":"Coulter","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2020071612082903500_B19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.gde.2009.11.002","article-title":"Targeting the PI3K signaling pathway in cancer","volume":"20","author":"Wong","year":"2010","journal-title":"Curr Opin Genet Dev"},{"issue":"1","key":"2020071612082903500_B20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.jaci.2014.02.020","article-title":"Occurrence of B-cell lymphomas in patients with activated phosphoinositide 3-kinase \u03b4 syndrome","volume":"134","author":"Kracker","year":"2014","journal-title":"J Allergy Clin Immunol"},{"issue":"9","key":"2020071612082903500_B21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/acsmedchemlett.7b00293","article-title":"Discovery of CDZ173 (leniolisib), representing a structurally novel class of PI3K delta-selective inhibitors","volume":"8","author":"Hoegenauer","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"2020071612082903500_B22","author":"Rao"},{"issue":"3","key":"2020071612082903500_B23","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.0902-4441.2003.00199.x","article-title":"Reference values for peripheral blood lymphocyte phenotypes applicable to the healthy adult population in Switzerland","volume":"72","author":"Bisset","year":"2004","journal-title":"Eur J Haematol"},{"issue":"2","key":"2020071612082903500_B24","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1111\/j.1365-2249.2010.04206.x","article-title":"Reference values for B cell subpopulations from infancy to adulthood","volume":"162","author":"Morbach","year":"2010","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"2020071612082903500_B25","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1002\/cyto.b.20536","article-title":"B cell subsets in healthy children: reference values for evaluation of B cell maturation process in peripheral blood","volume":"78","author":"Pi\u0105tosa","year":"2010","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"2020071612082903500_B26","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.clim.2009.05.020","article-title":"Refined characterization and reference values of the pediatric T- and B-cell compartments","volume":"133","author":"van Gent","year":"2009","journal-title":"Clin Immunol"},{"issue":"1-3","key":"2020071612082903500_B27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0047-6374(00)00199-8","article-title":"Increased expression of NK cell markers on T lymphocytes in aging and chronic activation of the immune system reflects the accumulation of effector\/senescent T cells","volume":"121","author":"Tarazona","year":"2000","journal-title":"Mech Ageing Dev"},{"issue":"2","key":"2020071612082903500_B28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/14740338.2013.752814","article-title":"Adverse events associated with mTOR inhibitors","volume":"12","author":"Pallet","year":"2013","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2020071612082903500_B29","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"2020071612082903500_B30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.clbc.2015.09.004","article-title":"Dosing and safety implications for oncologists when administering everolimus to patients with hormone receptor-positive breast cancer","volume":"16","author":"Rugo","year":"2016","journal-title":"Clin Breast Cancer"},{"issue":"16","key":"2020071612082903500_B31","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1002\/cncr.30069","article-title":"Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"issue":"13","key":"2020071612082903500_B32","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.1182\/blood-2011-05-352492","article-title":"The phosphoinositide 3\u2032-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia","volume":"118","author":"Hoellenriegel","year":"2011","journal-title":"Blood"},{"issue":"7642","key":"2020071612082903500_B33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nature21406","article-title":"Phosphatidylinositol 3-kinase \u03b4 blockade increases genomic instability in B cells","volume":"542","author":"Compagno","year":"2017","journal-title":"Nature"},{"issue":"1","key":"2020071612082903500_B34","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1148\/radiol.2015150887","article-title":"Spleen size is significantly influenced by body height and sex: establishment of normal values for spleen size at US with a cohort of 1200 healthy individuals","volume":"279","author":"Chow","year":"2016","journal-title":"Radiology"},{"key":"2020071612082903500_B35","doi-asserted-by":"crossref","DOI":"10.1007\/978-3-540-33395-1","article-title":"Pediatric Allergy, Asthma and Immunology","author":"Cantani","year":"2008"},{"issue":"4","key":"2020071612082903500_B36","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1159\/000381468","article-title":"Numbers of CD8+PD-1+ and CD4+PD-1+ cells in peripheral blood of patients with chronic lymphocytic leukemia are independent of Binet stage and are significantly higher compared to healthy volunteers","volume":"134","author":"Nov\u00e1k","year":"2015","journal-title":"Acta Haematol"},{"issue":"6","key":"2020071612082903500_B37","first-page":"517","article-title":"Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC\/BCR\/CAP Reference Material (CRM 470)","volume":"34","author":"Dati","year":"1996","journal-title":"Eur J Clin Chem Clin Biochem"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2307\/1403547\/blood801191.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/130\/21\/2307\/1403547\/blood801191.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,16]],"date-time":"2020-07-16T15:13:21Z","timestamp":1594912401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/130\/21\/2307\/36662\/Effective-activated-PI3K%CE%B4-syndrometargeted-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,23]]},"references-count":37,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2017,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-801191","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.731685017.793537909","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,23]]}}}